Cargando…
Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
BACKGROUND: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a no...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2500095/ https://www.ncbi.nlm.nih.gov/pubmed/18647414 http://dx.doi.org/10.1186/1471-2172-9-38 |
_version_ | 1782158296807899136 |
---|---|
author | Rosada, Rogério S Torre, Lucimara Gaziola de la Frantz, Fabiani G Trombone, Ana PF Zárate-Bladés, Carlos R Fonseca, Denise M Souza, Patrícia RM Brandão, Izaíra T Masson, Ana P Soares, Édson G Ramos, Simone G Faccioli, Lúcia H Silva, Célio L Santana, Maria HA Coelho-Castelo, Arlete AM |
author_facet | Rosada, Rogério S Torre, Lucimara Gaziola de la Frantz, Fabiani G Trombone, Ana PF Zárate-Bladés, Carlos R Fonseca, Denise M Souza, Patrícia RM Brandão, Izaíra T Masson, Ana P Soares, Édson G Ramos, Simone G Faccioli, Lúcia H Silva, Célio L Santana, Maria HA Coelho-Castelo, Arlete AM |
author_sort | Rosada, Rogério S |
collection | PubMed |
description | BACKGROUND: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally. RESULTS: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg). CONCLUSION: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease. |
format | Text |
id | pubmed-2500095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-25000952008-08-08 Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes Rosada, Rogério S Torre, Lucimara Gaziola de la Frantz, Fabiani G Trombone, Ana PF Zárate-Bladés, Carlos R Fonseca, Denise M Souza, Patrícia RM Brandão, Izaíra T Masson, Ana P Soares, Édson G Ramos, Simone G Faccioli, Lúcia H Silva, Célio L Santana, Maria HA Coelho-Castelo, Arlete AM BMC Immunol Research Article BACKGROUND: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally. RESULTS: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg). CONCLUSION: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease. BioMed Central 2008-07-22 /pmc/articles/PMC2500095/ /pubmed/18647414 http://dx.doi.org/10.1186/1471-2172-9-38 Text en Copyright © 2008 Rosada et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rosada, Rogério S Torre, Lucimara Gaziola de la Frantz, Fabiani G Trombone, Ana PF Zárate-Bladés, Carlos R Fonseca, Denise M Souza, Patrícia RM Brandão, Izaíra T Masson, Ana P Soares, Édson G Ramos, Simone G Faccioli, Lúcia H Silva, Célio L Santana, Maria HA Coelho-Castelo, Arlete AM Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes |
title | Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes |
title_full | Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes |
title_fullStr | Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes |
title_full_unstemmed | Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes |
title_short | Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes |
title_sort | protection against tuberculosis by a single intranasal administration of dna-hsp65 vaccine complexed with cationic liposomes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2500095/ https://www.ncbi.nlm.nih.gov/pubmed/18647414 http://dx.doi.org/10.1186/1471-2172-9-38 |
work_keys_str_mv | AT rosadarogerios protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT torrelucimaragazioladela protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT frantzfabianig protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT tromboneanapf protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT zaratebladescarlosr protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT fonsecadenisem protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT souzapatriciarm protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT brandaoizairat protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT massonanap protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT soaresedsong protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT ramossimoneg protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT faccioliluciah protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT silvaceliol protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT santanamariaha protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes AT coelhocasteloarleteam protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes |